Production of human albumin solution: a continually developing colloid

Matejtschuk, Paul; Dash, C. H.; Gascoigne, E.

doi:10.1093/bja/85.6.887

Cited by 85 publications

(73 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Cohn process is a milestone in the field of blood fractionation and it has been significantly modified over the past 60 years (Lane and Vallet, 1984;Matejtschuk et al, 2000). However, the Cohn process has not been thoroughly evaluated.…”

Section: Discussionmentioning

confidence: 99%

“…Although there are some disadvantages to this method, such as high pollution and no modernization, the Cohn process is universal and practical for use by pharmacological and medical industries. There are more than 10 process variations but only 2 main processes, the original Cohn process and the Kistler and Nitschmann variation, are commonly used (Matejtschuk et al, 2000). In the original Cohn process, as displayed in Table 3, the conditions for fraction I were 8% ethanol, pH 7.2, and -3°C, and those for fraction II+III were 25% ethanol, pH 6.9, and -5°C.…”

Section: Discussionmentioning

confidence: 99%

“…In general, 2 steps of the original Cohn process (Cohn fractions IV-1 and IV-4) were combined into 1 step (CFIV) in the Kistler and Nitschmann method. Currently, the original Cohn process is used by most American manufacturers, whereas the cost-effective and independent Kistler and Nitschmann variation has been widely accepted by many European and Asian fractionators (Matejtschuk et al, 2000). Therefore, Cohn fractions IV-1 and IV-4 are obtained in the United States, while CFIV is obtained in Asia and Europe using the different Cohn process variations.…”

Section: Discussionmentioning

confidence: 99%

“…The Cohn process, also known as cold ethanol fractionation, is a series of purification steps developed by Cohn et al (1946) during World War II to separate various proteins from blood plasma. The process is based on the differential solubility of albumin and other plasma proteins that can be controlled by adjusting pH, ethanol concentration, temperature, ionic strength, and protein concentration (Cohn et al, 1946;Matejtschuk et al, 2000). Valuable coagulation factors located in cryoprecipitate, such as factor VIII and von Willebrand factor, are removed by continuous flow centrifugation before the Cohn process.…”

Section: Introductionmentioning

confidence: 99%

“…Valuable coagulation factors located in cryoprecipitate, such as factor VIII and von Willebrand factor, are removed by continuous flow centrifugation before the Cohn process. Subsequently, fibrinogen, immunoglobulins, and albumin are sequentially precipitated (Cohn et al, 1946;Kistler and Nitschmann, 1962;Matejtschuk et al, 2000).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Cohn process influences the functional anticoagulant activity of human protein C

Wang¹,

Du²,

M³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Cohn fraction IV (CFIV) is a byproduct of a plasma fractionation process known as the Cohn process. It is an inexpensive source of protein C, retaining about 90% of protein C (PC) in human plasma. We investigated whether PC is affected during the Cohn process and evaluated correlations among coagulant activity, amidolytic activity and PC antigen during the Cohn process. CFIV was redissolved with citrate-buffered saline for 5 h at 4°C, and then centrifuged at 3500 g for 40 min at 4°C. Functional anticoagulant activity was measured with a one-stage coagulation method based on activated partial thromboplastin time. The functional amidolytic activity of PC was determined using chromogenic substrate assay, and measurement of PC antigen was performed by ELISA. In CFIV, anticoagulant activity declined significantly, with a loss of >80%, while amidolytic activity was not significantly altered, compared to PC antigen. Prior to the Cohn process, high-rank correlations were observed in cryosupernatant, with r s = 0.921 for anticoagulant and amidolytic activities (P = 0.009), 0.896 for anticoagulant activity and antigen (P = 0.014) and 0.832 for Cohn process influences protein C amidolytic activity and antigen (P = 0.031). After the Cohn process in CFIV, there was also a high correlation between amidolytic activity and antigen (r s = 0.782, P = 0.038). There were no significant correlations between anticoagulant activity and antigen (r s = 0.223, P = 0.653), or anticoagulant and amidolytic activity (r s = 0.236, P = 0.675). We conclude that the Cohn process significantly influences the anticoagulant activity of PC. Compared to the antigen, PC lost greater than 80% of its anticoagulant activity, but retained its amidolytic activity, during the Cohn process.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%